

an Open Access Journal by MDPI

Impact Factor 2.2 CiteScore 2.6

Kidney and Dialysis



mdpi.com/ journal/ kidneydial



Message from the Editor-in-Chief

Until recently, nephrology was not able to keep pace with oncology, cardiology, or rheumatology in the inexhaustible pipeline of new treatment options tested in an everincreasing number of randomized controlled trials. In recent years, we have been witnessing dramatically increased interest in the treatment of chronic kidney disease, e.g., diabetic kidney disease, glomerular disease, or autosomal dominant polycystic kidney disease, but also aimed more generally on the progression of chronic kidney disease and the complications of chronic kidney disease, such as anemia, or hyperkalemia. This progress has led to changing paradigms as reflected by several recently published KDIGO guidelines which now need to be updated much more frequently than before. To personalize treatment, we also need better diagnostic methods, including validated biomarkers reflecting the activity of the disease (including response to treatment) and predicting outcomes.

Editor-in-Chief

Prof. Dr. Francesco Locatelli

Associate Editors

Prof. Dr. Vito M. Campese Dr. Ciro Esposito Prof. Dr. Kunitoshi Iseki Prof. Dr. Vladimir Tesar Dr. Elena Zakharova

Aims

Kidney and Dialysis (ISSN 2673-8236) is an open access, peer-reviewed journal devoted to publishing articles on all aspects of the kidney. It focuses on normal kidney function and kidney disease, the preservation of kidney health and the treatment of kidney disease, from diet and medication to renal replacement therapy (dialysis and kidney transplantation). It also publishes research related to systemic conditions that affect the kidneys, such as diabetes and autoimmune disease, and systemic diseases that occur as a result of kidney disease, such as renal osteodystrophy and hypertension. Papers reporting new diagnosis methods and technologies for kidney function and disease will be welcome as well.

Scope

The scope of Kidney and Dialysis includes:

- Biomarkers in kidney disease;
- Chronic kidney disease (CKD), complications, and nutrition;
- Acute kidney injury (AKI)/critical care;
- Diabetic kidney disease;
- Glomerulonephritis;
- Pregnancy and CKD;
- Hypertension and nephrology;
- ADPKD;
- Renal vasculitis:
- Lupus nephritis;
- Hereditary kidney disease;
- Renal ischemia;
- Dialysis, hemodialysis (HD), peritoneal dialysis (PD);
- Dietary management and medication;
- Kidney transplantation;
- New diagnosis methods and technologies for kidney function and disease.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

A first decision is provided to authors approximately 50 days after submission; acceptance to publication is undertaken in 8.7 days (median values for papers published in this journal in the first half of 2025)

MDPI is a member of





















ORCID



Editorial Office kidneydial@mdpi.com

MDPI Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 mdpi.com

July 2025

